Clarivate Epidemiology’s coverage of osteoporosis (OSP) comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report the prevalence of OSP for each country…
Clarivate Epidemiology’s coverage of dermatitis / eczema comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report the prevalence of dermatitis / eczema…
Clarivate Epidemiology’s coverage of osteoporosis (OSP) comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report the prevalence of OSP for each country…
Myasthenia gravis (MG) is a rare neuromuscular disorder commonly caused by autoantibodies targeting acetylcholine (ACh) receptors and therefore affecting neuromuscular synaptic transmission at the…
Clarivate Epidemiology's coverage of axial spondyloarthritis (AxSpA) comprises epidemiological estimates of key patient populations across 45 countries worldwide. We report the diagnosed…
Clarivate Epidemiology’s coverage of axial spondyloarthritis (AxSpA) comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report the prevalence of AxSpA…
Clarivate Epidemiology’s coverage of axial spondyloarthritis (AxSpA) comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report the prevalence of AxSpA…
Clarivate Epidemiology’s coverage of axial spondyloarthritis (AxSpA) comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report the prevalence of AxSpA…
Clarivate Epidemiology’s coverage of axial spondyloarthritis (AxSpA) comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report the prevalence of AxSpA…
Clarivate Epidemiology’s coverage of axial spondyloarthritis (AxSpA) comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report the prevalence of AxSpA…
Clarivate Epidemiology’s coverage of axial spondyloarthritis (AxSpA) comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report the prevalence of AxSpA…
Clarivate Epidemiology’s coverage of axial spondyloarthritis (AxSpA) comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report the prevalence of AxSpA…
Clarivate’s Extrapolated Worldwide Coverage is the first and only evidence-based data set of epidemiological forecasts for key AxSpA patient populations covering 171 countries and more than 99%…
Clarivate Epidemiology’s coverage of axial spondyloarthritis (AxSpA) comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report the prevalence of AxSpA…
Clarivate Epidemiology’s coverage of axial spondyloarthritis (AxSpA) comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report the prevalence of AxSpA…